Literature DB >> 12578049

Inhaled nitric oxide fraction is influenced by both the site and the mode of administration.

E Sieffert1, L Ducros, M R Losser, D M Payen.   

Abstract

OBJECTIVE: Inhaled nitric oxide (NO) can be delivered continuously or sequentially (= during inspiration) at different locations of the ventilation circuit. We have tested the influence of locations, modes of NO administration and the ratio of the inspiratory time over the respiratory cycle time (I/I + E ratio) on the accuracy of NO fractions, delivered by 2 devices: Opti-NO and Flowmeter.
METHODS: We used a simplified lung model consisting of a ventilation circuit with a Y piece, a tracheal tube, a 150 ml dead-space volume and a 5 liter balloon. Three fractions (3, 6, 9 ppm) were administered continuously or sequentially, in controlled volume, in 4 different sites on the inspiratory branch above the Y piece: i) just after the water trap, ii) just before the Y piece; below the Y piece: iii) just after the Y piece, iv) into the endotracheal tube. In addition, different I/I + E ratios (25, 33, 50, 80%) were studied. The delivered NO fractions were measured in the balloon by chemiluminescence (CLD 700, Ecophysics). A linear regression analysis was used to test the relationship between administered and measured NO fractions for the 3 fractions (3, 6 and 9 ppm) in sequential and continuous modes. Intercept values were compared to zero and slopes to the identity line.
RESULTS: When NO was administered in the continuous mode upstream the Y piece, NO fractions measured in the balloon corresponded to the administered fractions. In contrast, below the Y piece, the measured NO fractions were significantly lower than the administered NO fractions. In the sequential mode, above and below the Y piece, the delivered NO fractions were within the manufacturer's range.
CONCLUSIONS: For the continuous NO delivery, locations above the Y piece are mandatory. However, locations below the Y piece imposes a sequential system, which can also be used for the sites located above the Y piece.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 12578049     DOI: 10.1023/a:1009971712989

Source DB:  PubMed          Journal:  J Clin Monit Comput        ISSN: 1387-1307            Impact factor:   2.502


  34 in total

1.  Safety guidelines for use of nitric oxide.

Authors:  L Foubert; B Fleming; R Latimer; M Jonas; A Oduro; C Borland; T Higenbottam
Journal:  Lancet       Date:  1992-06-27       Impact factor: 79.321

Review 2.  Delivery and monitoring of inhaled nitric oxide.

Authors:  J D Young; O J Dyar
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

3.  Variation of nitric oxide concentration during inspiration.

Authors:  M Sydow; F Bristow; J Zinserling; S J Allen
Journal:  Crit Care Med       Date:  1997-02       Impact factor: 7.598

4.  UK guidelines for the use of inhaled nitric oxide therapy in adult ICUs. American-European Consensus Conference on ALI/ARDS.

Authors:  B H Cuthbertson; P Dellinger; O J Dyar; T E Evans; T Higenbottam; R Latimer; D Payen; S A Stott; N R Webster; J D Young
Journal:  Intensive Care Med       Date:  1997-12       Impact factor: 17.440

5.  Inaccuracies of nitric oxide delivery systems during adult mechanical ventilation.

Authors:  H Imanaka; D Hess; M Kirmse; L M Bigatello; R M Kacmarek; W Steudel; W E Hurford
Journal:  Anesthesiology       Date:  1997-03       Impact factor: 7.892

6.  Therapeutic optimization including inhaled nitric oxide in adult respiratory distress syndrome in a polyvalent intensive care unit.

Authors:  B Levy; P E Bollaert; P Bauer; L Nace; G Audibert; A Larcan
Journal:  J Trauma       Date:  1995-03

7.  Inhaled nitric oxide for the adult respiratory distress syndrome.

Authors:  R Rossaint; K J Falke; F López; K Slama; U Pison; W M Zapol
Journal:  N Engl J Med       Date:  1993-02-11       Impact factor: 91.245

8.  Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects.

Authors:  D Journois; P Pouard; P Mauriat; T Malhère; P Vouhé; D Safran
Journal:  J Thorac Cardiovasc Surg       Date:  1994-04       Impact factor: 5.209

9.  Inhaled nitric oxide after mitral valve replacement in patients with chronic pulmonary artery hypertension.

Authors:  C Girard; J J Lehot; J C Pannetier; S Filley; P Ffrench; S Estanove
Journal:  Anesthesiology       Date:  1992-11       Impact factor: 7.892

10.  Guidelines for the safe administration of inhaled nitric oxide.

Authors:  O I Miller; D S Celermajer; J E Deanfield; D J Macrae
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-01       Impact factor: 5.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.